

# Anti-CD274 (PD-L1) Antibody-Pipeline Intelligence, 2019

<https://marketpublishers.com/r/A216C9AD667EN.html>

Date: December 2018

Pages: 60

Price: US\$ 1,000.00 (Single User License)

ID: A216C9AD667EN

## Abstracts

This report can be delivered to the clients within 1-2 Business Days.

CmaxInsight's, "Anti-CD274 (PD-L1) Antibody-Pipeline Intelligence, 2019", report provides comprehensive insights about pipeline drugs across this mechanism of action (MoA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Anti-CD274 (PD-L1) Antibody.

### Highlights and Scope of the Report

#### MoA Overview:

This section of the report provides comprehensive coverage of MoA enables the client to understand the landscape of the Anti-CD274 (PD-L1) Antibody.

#### Pipeline Covered:

This section mentions all the promising therapies in different phases of development including the NDA/BLA Filing, Phase III, Phase II, Phase I, Pre-Clinical and the Discovery. The section also details the products which have been dormant or discontinued during the trial stages of development.

#### Drug Profiles:

The pipeline guide features provide descriptive drug profiles for the pipeline products which comprise product description, Research and development, and product development activity.

## Product Description

It comprises of descriptive drug profiles for the pipeline products in terms of its mechanism of action, mode of administration, molecule type, chemical information, etc.

## Research and Development

This section of the report focusing on the clinical and pre-clinical activity which provide detailed information about the efficacy, safety and tolerability of pipeline drugs. A snapshot on the clinical trial of a pipeline therapy includes information about sponsor, stage of development, trial design, enrollment number, location, study start and primary completion date, and dosage frequency and formulation of the drug.

## Product Development Activity

This section of the report provides detail information about licensing and collaboration, funding & financing, designation, patent, technology, key milestones and other developmental activities.

## Therapeutic Assessment

The report comprises of comparative pipeline therapeutics assessment by stage of development, therapy type, indication / therapy area, molecule type, and route of administration across this MoA.

## Company Profile

Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial

## Methodology

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by CmaxInsight's team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

## Reasons to buy

Establish a comprehensive understanding of key competitor information, analysis, and insights to improve R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Discover in licensing and out licensing strategies by identifying potential partners with progressing projects for Anti-CD274 (PD-L1) Antibody to enhance and expand business potential and scope

Plan mergers and acquisitions successfully by identifying major players with the most promising pipeline therapeutics in the target demographic

Our extensive in-depth analysis on therapy portfolio support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the dormant or discontinued drugs

Develop strategic initiatives by understanding the focus areas of leading companies

Assess challenges and opportunities that influence Anti-CD274 (PD-L1) Antibody R&D

Please note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated mechanism of action.

## Contents

### **1. REPORT INTRODUCTION**

Executive Summary  
Key Findings

### **2. ANTI-CD274 (PD-L1) ANTIBODY - OVERVIEW**

### **3. PIPELINE THERAPEUTICS**

An Overview of Pipeline Products for Anti-CD274 (PD-L1) Antibody

### **4. COMPARATIVE ANALYSIS OF PIPELINE THERAPEUTICS**

### **5. PRODUCTS IN LAST / MID / EARLY CLINICAL STAGE DEVELOPMENT**

5.1 Drug Name: Company Name  
Product Description  
Research and Development (Clinical and Pre-clinical activity)  
Product Development Activities  
Key Development Milestone

### **6. PRODUCTS IN PRE-CLINICAL STAGE DEVELOPMENT**

6.1 Drug Name: Company Name  
Product Description  
Research and Development (Pre-clinical activity)  
Product Development Activities  
Key Development Milestone

### **7. PRODUCTS IN DISCOVERY STAGE DEVELOPMENT**

7.1 Drug Name: Company Name  
Product Description  
Research and Development (In-vitro activity)  
Product Development Activities  
Key Development Milestone

## **8. THERAPEUTIC ASSESSMENT OF PIPELINE ACTIVE PRODUCTS**

Pipeline Assessment by Route of Administration  
Pipeline Assessment by Stage and Route of Administration  
Pipeline Assessment by Molecule Type  
Pipeline Assessment by Stage and Molecule Type  
Pipeline Assessment by Indication / Therapy Area

## **9. DORMANT / DISCONTINUED PRODUCTS**

9.1 Drug Name: Company Name  
Product Description  
Research and Development  
Product Development Activities  
Reason for Dormancy / Discontinuation

## **10. COMPANY PROFILING**

Appendix  
Report Methodology  
Disclaimer  
About CmaxInsight  
Note: Certain sections of the table of contents would vary according to the availability of information

## List Of Tables

### LIST OF TABLES

Table 1: Total Pipeline Products for Anti-CD274 (PD-L1) Antibody

Table 2: Number of Products under Development by Companies

Table 3: Late stage Therapeutic Products

Table 4: Mid stage Therapeutic Products

Table 5: Early stage Therapeutic Products

Table 6: Pre-clinical stage Therapeutic Products

Table 7: Discovery stage Therapeutic Products

Table 8: Pipeline Analysis by Route of Administration

## List Of Figures

### LIST OF FIGURES

Figure 1: Total Pipeline Products for Anti-CD274 (PD-L1) Antibody

Figure 2: Late stage Therapeutic Products

Figure 3: Mid stage Therapeutic Products

Figure 4: Early stage Therapeutic Products

Figure 5: Pre-clinical stage Therapeutic Products

Figure 6: Discovery stage Therapeutic Products

Figure 7: Pipeline Analysis by Route of Administration

Figure 8: Pipeline Analysis by Stage and Route of Administration

Figure 9: Pipeline Analysis by Molecule Type

Figure 10: Pipeline Analysis by Stage and Molecule Type

Figure 11: Pipeline Analysis by Indication/ Therapy Area

Figure 12: Dormant / Discontinued Products

## I would like to order

Product name: Anti-CD274 (PD-L1) Antibody-Pipeline Intelligence, 2019

Product link: <https://marketpublishers.com/r/A216C9AD667EN.html>

Price: US\$ 1,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A216C9AD667EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970